RNU4-2 Saturated Editing Reveals New Recessive Neurodevelopmental Disorder
-
Research Background and Methods RNU4-2 is a core small nuclear RNA (snRNA) involved in the process of editing genetic information within cells, known as 'splicing'. The research team utilized the saturation genome editing (SGE) technique to individually mutate all the nucleotide sequences that make up the RNU4-2 gene. Subsequently, high-throughput screening was employed to measure the impact of each mutation on splicing efficiency and cell survival, thereby constructing a 'functional variant map' of the entire gene.
-
Key Findings: In contrast to dominant disorders, the study identified a new group of recessive variants that are functionally distinct from the dominant mutations known to cause ReNU syndrome.
- Existing Knowledge: ReNU syndrome exhibits a dominant genetic pattern, where the disease manifests even if the mutation is inherited from only one parent.
- New Discovery: The newly discovered variants only cause neurodevelopmental disorders when inherited from both parents (autosomal recessive), indicating a new type of disease that is clinically and genetically distinct from existing conditions.
- Significance and Clinical Value This study significantly improved the accuracy of clinical interpretation of the impact of RNU4-2 gene variants on actual patients. The findings provide a precise diagnostic guide for patients with rare neurodevelopmental disorders and are expected to serve as an essential database for establishing personalized treatment strategies in the future.
Nature, Published online: 08 April 2026; doi:10.1038/s41586-026-10334-9Saturation genome editing of RNU4-2 identifies the functional and clinical impact of variants across the entire gene and delineates variants that cause a new recessive neurodevelopmental disorder distinct from ReNU syndrome.
By comprehensively understanding the functional significance of genomic variants, we can accelerate the identification of the causes of unknown genetic diseases. Moreover, the clear distinction between dominant and recessive variants will have a direct impact on patient-specific genetic counseling and treatment development.